TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12837811
Drug: Vinorelbine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 25 mg/m2/wk and cisplatin 100 mg/m2 every 4 weeks (VC)
Study: 8672316
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine 1 ml kg‐1 with ketamine 0.5 mg kg‐1
Study: 1751269
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine 1 ml kg‐1
Study: 1751269
Drug: ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine 0.5 mg kg‐1 with normal saline 1 ml kg‐1
Study: 6762741
Drug: Combination chemotherapeutic
Normalized name: ANTIBIOTICS AND CHEMOTHERAPEUTICS, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapeutic regimen (cyclophosphamide, methotrexate, BCNU)
Study: 6762741
Drug: Combination chemotherapeutic
Normalized name: ANTIBIOTICS AND CHEMOTHERAPEUTICS, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapeutic regimen (cyclophosphamide, methotrexate, BCNU) plus intradermic BCG
Study: 30859956
Drug: 1-day initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1-day initiation regimen (ALNCD + 30mg oral aripiprazole)
Study: 30859956
Drug: 21-day oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 21-day oral aripiprazole regimen
Study: 28109729
Drug: Montelukast sodium
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast sodium and mometasone furoate (MF) therapy
Study: 25772444
Drug: Insulin degludec/insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin degludec/insulin aspart (IDegAsp) at doses of 0.4, 0.6, or 0.8 U/kg
Study: 16832639
Drug: Spa water
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa water therapy at 37 degrees C for 20 min a day, 5 days a week, for 2 weeks
Study: 16832639
Drug: Tap water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tap water therapy at 37 degrees C for 20 min a day, 5 days a week, for 2 weeks
Study: 16832639
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of spa water therapy vs tap water therapy
Study: 25236916
Drug: IVIG (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (intravenous immunoglobulin)
Study: 769147
Drug: Phase-release aspirin
Normalized name: aspirin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase-release aspirin tablets given twice daily
Study: 769147
Drug: Aspirin B.P.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin B.P. tablets given four times daily
Study: 769147
Drug: Phase-release aspirin
Normalized name: aspirin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase-release aspirin tablets
Study: 26348699
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Behavior Therapy (GCBT)
Study: 23754735
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg twice daily
Study: 23754735
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg twice daily
Study: 23754735
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg twice daily
Study: 23754735
Drug: 5 or
Normalized name: Acys-5 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 or 7.5 mg twice daily
Study: 10856103
Drug: IRS-IV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRS-IV therapy (intensified therapy with a doubling of cyclophosphamide or ifosfamide equivalent dosing per cycle)
Study: 10856103
Drug: IRS-IV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRS-IV therapy
Study: 8635369
Drug: Flunitrazepam, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam, 2 mg
Study: 6426846
Drug: L-carnitine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine administration (20 and 25 mg/kg body weight)
Study: 29805981
Drug: Diacerein 50
Normalized name: Diacerein 50 mg and glucosamine sulfate potassium chloride 1.5 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacerein 50 mg
Study: 22608375
Drug: Pharmacotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy and counseling for smoking cessation
Study: 15309457
Drug: Perilla extract
Normalized name: Perilla frutescens whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perilla extract (PE) containing 200 mg rosmarinic acid (RA)
Study: 7653809
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus injections of propofol (10 mg) after an initial IV bolus of 0.3 mg/kg
Study: 7653809
Drug: Conventional syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional syringe infusion pump (25-100 micrograms.kg-1.min-1) after an initial IV bolus of 0.3 mg/kg
Study: 7653809
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion (TCI) device with initial target concentration of 2 micrograms/mL adjusted between 1 and 4 micrograms/mL after an initial IV bolus of 0.3 mg/kg
Study: 2173391
Drug: Dronabinol, 10
Normalized name: Dronabinol, 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol, 10 mg plus placebo q.i.d.
Study: 2173391
Drug: Prochlorperazine, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine, 10 mg plus placebo q.i.d.
Study: 2173391
Drug: Dronabinol plus
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dronabinol plus prochlorperazine, each 10 mg q.i.d.
Study: 28732773
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral PrEP (tenofovir monotherapy or combination of tenofovir and emtricitabine)
Study: 24875466
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral feeding (EOF) starting on the first postoperative day
Study: 24875466
Drug: Late oral
Normalized name: Adalate Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late oral feeding (LOF) remaining nil by mouth until the return of bowel sounds
Study: 17112855
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 2 x 600 mg/d for 3 months (GI)
Study: 11376256
Drug: 24 hour
Normalized name: Immune 24 Hour +
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 hour two dose of 225 mL dilute contrast material
Study: 11376256
Drug: 24 hour
Normalized name: Immune 24 Hour +
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 hour five dose of 225 mL dilute contrast material
Study: 11376256
Drug: 48 hour
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 48 hour four dose of 225 mL dilute contrast material
Study: 11376256
Drug: 48 hour
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 48 hour six dose of 225 mL dilute contrast material
Study: 11376256
Drug: 48 hour
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 48 hour seven dose of 225 mL dilute contrast material
Study: 3566389
Drug: Multidose cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidose cold high potassium cardioplegia (27 mEq of KCl/L)
Study: 3566389
Drug: Initial cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial cold high potassium (27 mEq/L) cardioplegia followed by boluses of cold low potassium (7 mEq of KCl/L) solution
Study: 22751086
Drug: Rivastigmine (3-4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (3-4.5 mg/d)
Study: 15945136
Drug: Dietary supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplements usage
Study: 11844632
Drug: Single-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oral tramadol (75 mg or 112.5 mg) plus acetaminophen (650 mg or 975 mg)
Study: 11844632
Drug: Combination analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination analgesics (tramadol plus acetaminophen)
Study: 11844632
Drug: Components alone
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Components alone (tramadol or acetaminophen)
Study: 8522642
Drug: Orlistat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120 mg three times daily for 6 days)
Study: 7606629
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three times daily for 6 days)
Study: 1781415
Drug: Zileuton (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zileuton (200 mg to 800 mg)
Study: 6996930
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg clobazam (single daily dose)
Study: 6996930
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg diazepam (3-times daily)
Study: 11177119
Drug: Methyltestosterone (MT)
Normalized name: Methyltestosterone
DrugBank: Methyltestosterone (DB06710)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyltestosterone (MT) 40 mg/d for 3 days, then 240 mg/d for 3 days
Study: 9394322
Drug: Dermatan sulphate
Normalized name: Dermatan sulphate
DrugBank: Dermatan sulfate (DB15880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermatan sulphate (DS) at 4 mg/kg as a predialysis intravenous bolus followed by continuous infusion of 0.65 mg/kg/h
Study: 28337949
Drug: Masters‐Johnson sex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masters‐Johnson sex therapy (MJST)
Study: 26194791
Drug: Op Volle
Normalized name: Schinus molle pollen
DrugBank: Schinus molle pollen (DB10483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Op Volle Kracht (OVK) plus Treatment as Usual (TAU)
Study: 18437408
Drug: Control (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (combination of five different components)
Study: 14565783
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (acetylsalicylic acid) therapy
Study: 10958177
Drug: Glandular symptoms
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glandular symptoms (G)
Study: 8840054
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia followed by postoperative intravenous analgesia (GA)
Study: 15772563
Drug: Raloxifene 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 150 mg/d
Study: 9848300
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE) 0.625 mg/d
Study: 8153939
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate 1000 micrograms twice daily
Study: 28825570
Drug: self-injection
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: self-injection
Study: 28825570
Drug: home treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: home treatment
Study: 28825570
Drug: early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: early treatment decision
Study: 28825570
Drug: sharing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: sharing treatment dose
Study: 28825570
Drug: access to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: access to medication
Study: 26214772
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m2 via four weekly intravenous drip)
Study: 26214772
Drug: Vincristine (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine (0.02 mg/kg by intravenous drip once a week for three months)
Study: 21261975
Drug: Early parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early parenteral nutrition (PN) initiated within 24-48 hours after ICU admission
Study: 21261975
Drug: Late parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late parenteral nutrition (PN) initiated on day 8 when caloric target is not reached
Study: 16514301
Drug: Atazanavir/ritonavir (300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir (300/100 mg) QD
Study: 16514301
Drug: Lopinavir/ritonavir (400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (400/100 mg) BID
Study: 14641992
Drug: Standard postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard postoperative chemotherapy
Study: 14641992
Drug: Epidermal growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidermal growth factor receptor/tyrosine kinase inhibitor gefitinib
Study: 14641992
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of new approaches and standard therapy
Study: 10837389
Drug: Vigabatrin (VGB)
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vigabatrin (VGB) therapy
Study: 8451470
Drug: Midazolam-Propofol combination
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Midazolam-Propofol combination
Study: 28729473
Drug: Automated oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated oxygen titration
Study: 24408211
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg mCPP
Study: 24408211
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg mCPP
Study: 10526939
Drug: Nitrate infusion
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate infusion (isosorbide dinitrate: ISDN or nitroglycerin: TNG) for 30 minutes (group A)
Study: 10526939
Drug: Nitrate infusion
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate infusion for 48 hours (group B)
Study: 10526939
Drug: Nitrate infusion
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate infusion for 78 hours (group C)
Study: 7481324
Drug: Combined local
Normalized name: Local hemostatic combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined local treatment (surgery plus radiotherapy)
Study: 31821466
Drug: Zinc bis-glycinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc bis-glycinate (15 mg elemental zinc), twice per day
Study: 24007754
Drug: Lorazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (2 mg given by mouth)
Study: 21311047
Drug: Health promotion
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health promotion intervention (patient education, health promotion coaching, medication management, physician care management)
Study: 11072398
Drug: 21 mg/day
Normalized name: nicotine 21 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 mg/day nicotine patch
Study: 11072398
Drug: 35 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg/day nicotine patch
Study: 11072398
Drug: 42 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 42 mg/day nicotine patch
Study: 11072398
Drug: 0 mg/day
Normalized name: RibaTab 800 mg/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/day nicotine patch (control)
Study: 7564894
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg caffeine/kg lean body mass
Study: 2207419
Drug: Potassium 60
Normalized name: potassium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium 60 mmol/day in combination with magnesium 20 mmol/day
Study: 7461014
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of digoxin 1.25 mg
Study: 7461014
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of digoxin 0.625 mg
Study: 7461014
Drug: Maintenance dose
Normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance dose of digoxin 0.25 mg
Study: 7461014
Drug: Maintenance dose
Normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance dose of digoxin 0.125 mg
Study: 31836261
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin 40UI
Study: 24857519
Drug: LNAA tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNAA tablets plus supplementation with tryptophan (Trp) and tyrosine (Tyr) tablets
Study: 24857519
Drug: LNAA tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNAA tablets plus placebo
Study: 17616778
Drug: Entrée portion
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entrée portion size of 500 g and energy density of 1.8 kcal/g
Study: 17616778
Drug: Entrée portion
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entrée portion size of 250 g and energy density of 1.3 kcal/g
Study: 15222514
Drug: Ibuprofen and
Normalized name: Ibuprofen and Famotidine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen and combined technique of physical therapy
Study: 25654309
Drug: Sham/unsuccessful bronchoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham/unsuccessful bronchoscopic treatment (Control, n = 10)
Study: 17109595
Drug: Chromium picolinate
Normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chromium picolinate (600 microg) and biotin (2 mg/day)
Study: 11739451
Drug: Ghrelin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ghrelin infusion (0.1 microg/kg.min)
Study: 3557711
Drug: Verapamil (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (0.1 mg/kg as a bolus followed by chronic infusion of 0.005 mg/kg/min for 3 min, intravenously)
Study: 22508203
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (1.5 μg/kg body weight)
Study: 22508203
Drug: Intravenous PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PCA with Piritramide
Study: 20723651
Drug: Candesartan 32
Normalized name: candesartan 32 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 32 mg 1 time/day
Study: 15673877
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tramadol and morphine
Study: 12919771
Drug: Dronedarone 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronedarone 800 mg daily
Study: 12919771
Drug: Dronedarone 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronedarone 1600 mg daily
Study: 6261677
Drug: Prednisolone, starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone, starting dose 60 mg daily
Study: 6261677
Drug: Prednisolone, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone, 10 mg/kg in rats
Study: 21118875
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of Edmonston‐Zagreb measles vaccine at 4.5 and 9 months of age (group A)
Study: 21118875
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of Edmonston‐Zagreb measles vaccine at 9 months of age (group B)
Study: 21118875
Drug: Schwarz measles
Normalized name: measles virus vaccine live, attenuated Schwarz strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz measles vaccine at 9 months of age (group C)
Study: 15662518
Drug: Atypical antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotic drugs
Study: 10073377
Drug: Conventional antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antipsychotic drugs
Study: 9129531
Drug: EchiTab (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: EchiTab (one vial, 10 ml; 0.5 g protein)
Study: 9129531
Drug: Institute Pasteur
Normalized name: Human fibrinogen concentrate, pasteurized
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Institute Pasteur Serum (Ipser) Africa antivenom (four ampules, 40 ml; 2.12 g protein)
Study: 3286518
Drug: Ciprofloxacin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (250 mg/b.i.d.)
Study: 3286518
Drug: Cefalexin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefalexin (1 g/t.i.d.)
Study: 20639624
Drug: Bisphosphonates (BPs)
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonates (BPs) treatment
Study: 12372131
Drug: FP 200
Normalized name: PEANUT ALLERGEN-DNFP 200MG (LEVEL 9) POWDER,ORAL,PKT,30
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP 200 microg/day (constant dose group)
Study: 10669910
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (GFJ) with 300 mg of phenytoin (DPH)
Study: 10669910
Drug: Water with
Normalized name: sterile water with electrolytes injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water with 300 mg of phenytoin (DPH)
Study: 8960728
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon beta-1b (8.0 million units)
Study: 8960728
Drug: Low-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose interferon beta-1b (1.6 million units)
Study: 2012909
Drug: Day-hospital treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day-hospital treatment
Study: 7044656
Drug: Attempted improved
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attempted improved therapy (A group)
Study: 7044656
Drug: Usual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual therapy (U group)
Study: 26374297
Drug: Extended-release niacin/laropiprant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin/laropiprant (ERN/LRP)